Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Gastroenterology and hepatology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Chronic pancreatitis

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Progressive jaundice, rapid unexplained weight loss, a new mass, gastrointestinal bleeding, fever, persistent vomiting or a substantial change in pain requires urgent re-imaging and specialist review for pancreatic cancer, obstruction, pseudocyst, infection or bleeding rather than automatic attribution to chronic pancreatitis.

Overview

Diagnose irreversible pancreatic disease, treat pain without stigma, replace exocrine function, detect type 3c diabetes and malnutrition, and select duct or cancer pathways safely.

Repeated injury activates fibrosis, distorts pancreatic ducts and reduces acinar and islet tissue. Pain may arise from inflammation, duct hypertension, stones, strictures, pseudocysts, neural remodelling or complications outside the pancreas. Symptoms fluctuate, and some people become less painful as the gland fails; pain relief therefore does not prove disease resolution. Diagnosis integrates history, cross-sectional imaging and exocrine/endocrine assessment. Normal early CT does not exclude disease, but neither do non-specific pain and alcohol exposure establish it.

Exocrine pancreatic insufficiency causes maldigestion before overt vitamin levels necessarily fall. Stool becomes oily, difficult to flush, frequent or pale; weight and muscle decline despite intake. Pancreatic enzyme replacement therapy supplies lipase, protease and amylase at the same time as food. Poor response usually prompts a review of adherence, timing, dose, product availability, acid inactivation and alternative conditions such as coeliac disease, bile-acid diarrhoea or small-intestinal bacterial overgrowth rather than immediate abandonment.

Aetiology

01

Alcohol and smoking

Sustained harmful alcohol exposure is an important cause, while smoking independently accelerates progression and compounds cancer and cardiovascular risk.

02

Recurrent or inherited injury

Repeated acute pancreatitis, genetic susceptibility, metabolic disorders and anatomical variants can drive chronic fibro-inflammatory damage, including in younger patients.

03

Autoimmune or obstructive disease

Autoimmune pancreatitis, duct strictures, stones and pancreatic tumours can produce chronic inflammation and require cause-specific treatment rather than a lifestyle assumption.

Pathophysiology

  1. 1
    Repeated acinar injury

    Recurrent inflammation and cellular stress activate fibrogenic pathways, replacing functioning pancreatic tissue with scar and distorted ducts.

  2. 2
    Ductal distortion and pain

    Strictures, stones and altered duct pressure combine with neural inflammation and central sensitisation to produce variable recurrent or persistent pain.

  3. 3
    Exocrine and endocrine loss

    Progressive acinar and islet destruction reduces digestive enzymes, bicarbonate and insulin, causing maldigestion, deficiency and pancreatogenic diabetes.

Clinical features and red flags

Pain-predominant disease

Recurrent or continuous epigastric pain radiating to the back, often aggravated by food, may precede obvious malabsorption or diabetes by years.

Exocrine insufficiency

Steatorrhoea, weight loss, bloating, diarrhoea, sarcopenia and vitamin or mineral deficiency indicate inadequate digestive enzyme delivery and require nutrition support.

Type 3c diabetes

Hyperglycaemia arising after pancreatic damage can be brittle because insulin and glucagon secretion are impaired and intake or absorption fluctuates.

Obstructed duct phenotype

A dilated main duct upstream from dominant stone or stricture with pain suggests pressure-related disease suitable for specialist decompression or surgery assessment.

Cancer or acute complicationRed flag

Progressive jaundice, rapid unexplained weight loss, a new mass, gastrointestinal bleeding, fever, persistent vomiting or substantially altered pain requires urgent re-imaging and specialist review.

Investigations

  1. 01
    Pancreatic-protocol contrast CTFirst step
    Why
    Assess calcification, atrophy, duct enlargement, stones, inflammatory mass, pseudocyst, obstruction and possible malignancy.
    Interpretation and limitations
    Advanced morphological disease may be diagnostic; a normal study does not exclude early chronic pancreatitis and should prompt phenotype-led specialist testing.
  2. 02
    MRI with MRCP
    Why
    Delineate duct strictures, side branches, stones, cystic complications and a possible mass without ionising radiation.
    Interpretation and limitations
    Duct irregularity supports chronic injury, while an abrupt cutoff or upstream atrophy raises tumour concern and requires cancer-pathway review.
  3. 03
    Endoscopic ultrasound
    Why
    Evaluate subtle parenchymal and duct changes or obtain planned tissue when CT and MRCP leave clinically important uncertainty.
    Interpretation and limitations
    Minor EUS features are not perfectly specific and should not label non-specific pain in isolation; focal lesions need MDT-context sampling.
  4. 04
    Faecal elastase
    Why
    Support diagnosis of moderate or severe pancreatic exocrine insufficiency in a compatible nutrition and stool phenotype.
    Interpretation and limitations
    Low concentration supports insufficiency, but watery diarrhoea dilutes the sample; a normal result may not exclude mild disease and PERT does not invalidate the assay.

Differential diagnosis

01

Pancreatic cancer

New or changing pain, weight loss, jaundice, focal duct cut-off or a mass requires urgent cancer assessment even in established chronic pancreatitis.

02

Peptic or biliary disease

Endoscopic ulceration, gallstones with characteristic attacks or duct obstruction provides an alternative explanation for upper-abdominal pain.

03

Functional or neuropathic pain

Pain severity may persist without active structural progression; objective pancreatic findings and careful assessment avoid both dismissal and repeated invasive procedures.

Management

01NutritionExocrine replacement planFirst stepSymptoms, nutritional decline or testing supports pancreatic exocrine insufficiency.+
  1. 1AlternativeRefer to a pancreatic-experienced dietitian and document stool, intake, weight, muscle, alcohol, smoking, vitamins and alternative malabsorption diagnoses.
  2. 2Start an available enteric-coated pancreatin product with all meals and snacks, teaching the person to spread the prescribed amount through eating.
  3. 3Review weight and stool response, then optimise timing and enzyme strength before adding acid suppression or investigating another cause.
  4. 4Use the current Specialist Pharmacy Service equivalence resource during supply disruption and explain any product or capsule-count change clearly.
02PainMultidisciplinary pain pathwayPersistent or recurrent pain impairs eating, sleep, work or quality of life despite initial treatment.+

Complications

01

Pancreatic exocrine insufficiency

Maldigestion causes steatorrhoea, weight loss, sarcopenia and fat-soluble vitamin deficiency, sometimes before patients recognise oily stool.

02

Type 3c diabetes

Loss of islet hormones produces diabetes with variable insulin needs and vulnerability to hypoglycaemia, particularly alongside malnutrition or alcohol use.

03

Ductal and vascular complications

Pseudocysts, biliary or duodenal obstruction, splenic-vein thrombosis, pseudoaneurysm bleeding and elevated pancreatic cancer risk require specialist follow-up.

Monitoring and follow-up

  • At least annually, review stool, weight, dietary intake, muscle function, FBC and relevant vitamins or minerals with the specialist-centre protocol.
  • Record HbA1c at minimum six-month intervals and assess symptoms or capillary glucose sooner when diabetes or hypoglycaemia is suspected.
  • Arrange two-yearly adult bone-density assessment, then integrate the result with fracture history, falls, vitamin D, calcium and smoking.
  • During PERT titration, follow capsule timing, amount eaten, stool quality, weight and supply continuity rather than relying only on repeat faecal elastase.
  • For long-term analgesics, assess pain interference, function, mood, constipation, sedation, early refill and overdose risk at every structured review.
  • Escalate a new mass, duct cutoff, jaundice, rapid weight loss or sudden diabetic deterioration to the pancreatic cancer pathway.

Special situations

Pain can fade late

Reduced pain may accompany gland burnout while malnutrition and diabetes worsen, so it is not necessarily recovery.

Enzymes meet food

PERT taken long before or after eating cannot mix effectively with the meal, even if the nominal daily dose seems high.

Elastase can dilute

A watery sample may create a spuriously low concentration and should be repeated on a formed specimen when doubt matters.

Type 3c is unstable

Loss of both insulin and glucagon, inconsistent absorption and alcohol or reduced intake make hypoglycaemia unusually hazardous.

Cancer changes the baseline

A new pattern deserves new imaging; long-standing pancreatic pain is not a licence to normalise progressive alarm features.

Common pitfalls

  1. 01

    Attributing chronic pancreatitis to alcohol without evaluating other causes or offering support.

  2. 02

    Giving one enzyme capsule daily rather than matching replacement to every meal and snack.

  3. 03

    Restricting dietary fat so severely that calorie and vitamin deficiency worsens.

  4. 04

    Treating faecal elastase as infallible in a watery stool sample.

  5. 05

    Coding pancreatic diabetes as routine type 2 disease without hypoglycaemia planning.

  6. 06

    Explaining new weight loss or jaundice as inevitable chronic pancreatitis without cancer assessment.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Gastroenterology and hepatologyOriginal SBA

Painful main-duct obstruction

An adult with chronic pancreatitis has disabling pain and imaging shows a dilated main pancreatic duct obstructed by stones. Which first-line definitive approach does NICE advise considering?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Gastroenterology and hepatology topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG104 chronic pancreatitis recommendations
  • BNF exocrine pancreatic insufficiency summary
  • BNF pancreatin drug monograph
  • NICE CG100 alcohol-related pancreatitis recommendations
  • NICE NG85 inherited pancreatic cancer surveillance

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Long-term care is multidisciplinary. Pain treatment combines alcohol and smoking support, non-opioid and neuropathic strategies, psychology, dietetics and anatomical correction when appropriate. NICE places surgery first-line for painful chronic pancreatitis with main pancreatic duct obstruction, while shock-wave lithotripsy may suit a dominant stone when surgery is unsuitable. Diabetes, osteoporosis, pseudocysts, biliary or duodenal obstruction, thrombosis and cancer risk need planned surveillance. Hereditary pancreatitis requires specialist genetic counselling and a defined cancer-monitoring programme rather than improvised population screening.

Key points

  • Chronic pancreatitis is progressive fibro-inflammatory pancreatic damage causing recurrent or persistent upper-abdominal pain, ductal or calcific structural change and eventual exocrine or endocrine failure.
  • Do not assume alcohol causation because a person drinks: smoking, genetic variants, autoimmune disease, recurrent acute episodes, obstruction, anatomical factors and metabolic disease require consideration.
  • CT demonstrates calcification, atrophy, duct dilatation, stones, pseudocyst and mass; MRI/MRCP and EUS help when early or ductal disease remains uncertain and the result would change care.
  • Steatorrhoea, weight loss, sarcopenia, bloating and fat-soluble vitamin deficiency suggest exocrine insufficiency; watery stool can falsely lower faecal elastase and results need clinical interpretation.
  • Pancreatic enzyme replacement is taken with every meal and nourishing snack, distributed through eating and titrated to symptoms, weight and nutrition rather than prescribed as a token fixed capsule.
  • Type 3c diabetes combines insulin deficiency with impaired glucagon counter-regulation and malabsorption, producing unstable glucose and substantial hypoglycaemia risk that merits specialist review.
  • NICE advises exocrine and nutrition assessment at least annually, HbA1c at least every six months and bone-density assessment every two years in adults with chronic pancreatitis.
  • New weight loss, jaundice, a changed pain pattern, duct cutoff, worsening diabetes or gastric-outlet symptoms require prompt pancreatic-cancer assessment rather than automatic attribution to chronic disease.
05
Nutrition and micronutrient profile
Why
Assess weight trajectory, BMI, grip or muscle status, FBC, ferritin, albumin, magnesium and vitamins including D, adding others by phenotype.
Interpretation and limitations
Albumin is strongly influenced by inflammation and is not a standalone nutrition marker; combined deficiencies can mask expected blood-count patterns.
  • 06
    HbA1c and glucose assessment
    Why
    Screen at least six-monthly for diabetes and investigate symptoms of hypo- or hyperglycaemia between planned checks.
    Interpretation and limitations
    HbA1c can be misleading with anaemia or rapid glucose change; type 3c classification informs insulin, education and hypoglycaemia planning.
  • 07
    Dual-energy X-ray absorptiometry
    Why
    Measure bone density every two years in adults under NICE guidance because malabsorption and lifestyle factors increase fragility risk.
    Interpretation and limitations
    Low density should trigger fracture-risk, vitamin D, calcium, hormone, exercise and medication review rather than supplementation alone.
  • 1Re-image a changed phenotype and exclude pseudocyst, ulcer, biliary or duodenal obstruction, splenic-vein complication and pancreatic malignancy.
  • 2Offer smoking cessation and alcohol support without making care conditional, and combine non-opioid, neuropathic, psychological and functional approaches.
  • 3First lineDiscuss painful main-duct obstruction at a specialist centre; NICE advises considering surgery first-line and shock-wave lithotripsy for a dominant stone if surgery is unsuitable.
  • 4EscalationIf opioids are used, set functional goals, review benefit and harm, minimise escalation and coordinate one prescribing team with dependence safeguards.
    • 03LifetimeComplication surveillanceA diagnosis of chronic or hereditary pancreatitis has been established and requires continuing shared care.+
    1. 1Assess exocrine function and malnutrition clinically and biochemically at least yearly, replacing identified vitamins and minerals with specialist agreement.
    2. 2Check HbA1c at least every six months and review people with type 3c diabetes for insulin benefit, glucose education and hypoglycaemia risk.
    3. 3Arrange adult bone-density measurement every two years and address exercise, falls, calcium, vitamin D and osteoporosis treatment when indicated.
    4. 4Investigate new alarm symptoms urgently; consider annual cancer monitoring in hereditary pancreatitis through a specialist programme and current NICE pancreatic-cancer criteria.
    Key medicines and prescribing safety4 treatments · regimens, roles and cautions+
    Replaces deficient digestive enzymes to reduce steatorrhoea, improve absorption, restore weight and prevent micronutrient complications.

    Enteric-coated pancreatin replacement

    Prescribe an individual lipase-based amount with every meal and snack, spread through eating and titrated using current BNF and specialist guidance.

    Swallow microspheres without crushing, avoid inhalation or oral mucosal contact, check porcine acceptability, and review very high doses because fibrosing colonopathy is reported.

    Reduces gastric acid degradation of enzyme microspheres in selected people with continuing maldigestion.

    Proton-pump inhibitor adjunct

    Use a standard current BNF adult regimen as a specialist-informed trial when adequate correctly timed pancreatin remains clinically ineffective.

    First correct timing, dose and adherence; review infection, magnesium, bone and long-term indication risks and do not mask another malabsorption cause.

    Replaces inadequate endocrine secretion when non-insulin measures cannot safely control pancreatic diabetes or catabolic symptoms occur.

    Insulin for type 3c diabetes

    Choose a personalised basal-bolus or other specialist diabetes regimen with glucose monitoring matched to meals, malabsorption and hypoglycaemia risk.

    Glucagon response may be impaired and intake variable; teach hypoglycaemia treatment, driving rules, sick-day care and injection-site rotation, and coordinate PERT.

    Targets a neuropathic component of chronic pancreatic pain as part of broader multidisciplinary treatment.

    Neuropathic pain medicine

    Use one NICE-recommended neuropathic-pain option with slow titration, a defined functional target and scheduled assessment of benefit and harm.

    Sedation, dizziness, falls, mood effects, renal dosing and dependence potential vary by agent; stop gradually when ineffective and avoid unsafe polypharmacy.